Duration of the project 2015-2022. TBD-Biodiscovery is a partner in the subproject 2.1.1. „Development of new toxins for antibody drug conjugates used in the modern anticancer treatment“. Project’s aim is to develop new toxins and linkers for ADC-s. TBD Biodiscovery development activities are co-funded by European Regional Development Fund with 961 848 €. The CCHT project is a part of Competence Centres programme.
(TBD-Biodiscovery on Tervistehnoloogiate Arenduskeskus AS projekti CCHT (EU48695) koostööpartner. Alamprojekti 2.1.1. „Development of new toxins for antibody drug conjugates used in the modern anticancer treatment“ raames tegeletakse uute ADC toksiinide arendamisega. TBD Biodiscovery OÜ saab antud projektiga toetust 961 848 €. CCHT projekt on osa EAS Tehnoloogia Arenduskeskuste meetmest.)